ruxolitinib Archive — Page 1 of 1

3D medical illustration showing red blood cells interspersed with larger purple-and-white spherical cells, representing an acute lymphoblastic leukemia bone marrow smear.

April 20, 2021

New therapeutic strategy for leukemia syndrome

Using primary cells from patients with chronic myelomonocytic leukemia, Vanderbilt researchers found synergistic inhibition of cell viability and proliferation, suggesting a new treatment strategy.

By Leigh MacMillan

Portrait of Madan Jagasia wearing glasses, a dark suit, white shirt, and patterned tie against a brown background.

June 13, 2019

Treatment approved for patients with acute graft-versus-host disease

The U.S. Food and Drug Administration (FDA) recently approved ruxolitinib, the first drug for patients with acute graft-versus-host disease (GVHD) who have an inadequate response to steroid treatment. VUMC’s Madan Jagasia, MBBS, MS, MMHC, was a lead investigator of the REACH1 trial that was the basis for the FDA approval.

By Tom Wilemon